• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
Shop

Horizons Psychedelic ETF Performs 1:4 Share Consolidation

Microdose NewsDesk by Microdose NewsDesk
August 3, 2022
in Finance
Reading Time: 4 mins read
A A
Horizons Psychedelic ETF Performs 1:4 Share Consolidation

Shareholders of the Horizons Psychedelic Stock Index ETF (PSYK) might have noticed a sudden and drastic price change this week. No, unfortunately, the entire sector did not jump 400%, but rather Horizons has performed a consolidation on several of their ETFs, including PSYK.

So consider this a public service announcement, meant to help clear things up for investors wondering if there’s a glitch in their Questrade or Robinhood apps.

The PSYK ETF was consolidated at a 1:4 ratio and “the net asset value per Security is increased by the same ratio as the Security consolidation so that the Security consolidation has no impact on the value of the investor’s total position.”

Following this 1:4 consolidation, the ticker price has moved from the $2.95 range to around $11.80.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

See the full press release below.

Continue on your trip...

Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds

A Pioneering Push in Cancer Treatment: Enveric Biosciences Advances with Cannabinoid Therapies

Unlocking New Horizons: Enveric Biosciences’ Strategic Moves in Biotechnology

 

 

HORIZONS ETFs ANNOUNCES ETF CONSOLIDATIONS

 

TORONTO, July 13, 2022 /CNW/ – Horizons ETFs Management (Canada) Inc. (“Horizons ETFs“) has announced today that it intends to consolidate, as applicable, shares or units (the “Securities” or each individually a “Security”) of certain ETFs (the “Consolidating ETFs“) as indicated in the table below.

After the close of trading on Friday, July 29, 2022, on the Toronto Stock Exchange and the NEO Stock Exchange, the Securities of each Consolidating ETF will be consolidated based on the ratio (the “Consolidation Ratio“) set out below and will begin trading on a post-consolidated basis on Tuesday, August 2, 2022, the effective date of the consolidation:

ETF Name Ticker Consolidation Ratio
BetaPro Bitcoin ETF HBIT / HBIT.U 1:4
BetaPro Crude Oil Inverse Leveraged Daily Bear ETF HOD 1:4
BetaPro Marijuana Companies 2x Daily Bull ETF HMJU 1:2
BetaPro S&P/TSX Capped Energy™ -2x Daily Bear ETF HED 1:4
Horizons Marijuana Life Sciences Index ETF HMMJ / HMMJ.U 1:2
Horizons Psychedelic Stock Index ETF PSYK 1:4
Horizons US Marijuana Index ETF HMUS / HMUS.U 1:4

When a Security consolidation occurs, the net asset value per Security is increased by the same ratio as the Security consolidation so that the Security consolidation has no impact on the value of the investor’s total position. An investor’s cost per Security is also increased by the same ratio as the Security consolidation, although their total cost remains unchanged.

No fractional Securities will be issued. Where the consolidation results in a fractional Security, the number of post-consolidation Securities will be rounded down to the nearest whole Security, in the case of a fractional interest that is less than 0.5, or rounded up to the nearest whole number, in the case of a fractional interest that is 0.5 or greater.

Horizons ETFs reserves the right to cancel or amend these corporate actions if we deem it appropriate to do so, before the effective date of Tuesday, August 2, 2022.

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Securityholder Information

Lasix Now For Sale

Securityholders of the Consolidating ETFs do not need to take any action to affect these transactions. Securityholders will have their brokerage accounts automatically updated to reflect the consolidations. A Securityholder’s broker may take several days to reflect these transactions in the Securityholder’s account (the “Settlement Period“). However, the Securityholder is still able to trade the Securities of the Consolidating ETFs during this time. If they wish to do so, Horizons ETFs recommends investors contact their broker by phone during the Settlement Period in order to trade the post-consolidation Securities.

About Horizons ETFs Management (Canada) Inc. (www.HorizonsETFs.com)

Horizons ETFs Management (Canada) Inc. is an innovative financial services company and offers one of the largest suites of exchange traded funds in Canada. The Horizons ETFs product family includes a broadly diversified range of solutions for investors of all experience levels to meet their investment objectives in a variety of market conditions. Horizons ETFs has over $21 billion of assets under management and 104 ETFs listed on major Canadian stock exchanges.

Commissions, management fees and expenses all may be associated with an investment in exchange traded products managed by Horizons ETFs Management (Canada) Inc. (the “Horizons Exchange Traded Products”). The Horizons Exchange Traded Products are not guaranteed, their value changes frequently and past performance may not be repeated. Certain Horizons Exchange Traded Products may have exposure to leveraged investment techniques that magnify gains and losses and which may result in greater volatility in value and could be subject to aggressive investment risk and price volatility risk. Such risks are described in the prospectus. The prospectus contains important detailed information about the ETF. Please read the relevant prospectus before investing.

For a summary of the risks of an investment in the Consolidating ETF, please see the specific risks set out in the applicable prospectus.  The Consolidating ETF trades like a stock, fluctuates in market value and may trade at a discount to its net asset value, which may increase the risk of loss.

This communication is intended for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase the Horizons Exchange Traded Products and is not, and should not be construed as, investment, tax, legal or accounting advice, and should not be relied upon in that regard. Individuals should seek the advice of professionals, as appropriate, regarding any particular investment.

SOURCE Horizons ETFs Management (Canada) Inc.

For further information: Contact Horizons ETFs at 1-866-641-5739 (toll-free) or (416) 933-5745, info@horizonsetfs.com

Tags: ETFPSYK ETF
Microdose NewsDesk

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Next Post
Microdose Announces Braxia Scientific as Wonderland Gold Sponsor

Braxia Acquires KetaMD, Enters U.S. Telemedicine Industry

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.